What the Study Found (In Plain English)
Published in Journal of gynecologic oncology (2021), this phase iii randomized trial evaluating 137 human participants investigated: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m² every 4 weeks. Key clinical takeaway: Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely. However, recommendation of dose reduction of PLD should be based both on efficacy and safety.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Journal of gynecologic oncology, 2021-01-15; N = 137; Rigor 82/100): Non-inferiority of 2 PLD dosing schedule was not confirmed because the trial was closed prematurely. However, recommendation of dose reduction of PLD should be based both on efficacy and safety.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.